MHRA Strategy 2030

The Medicines and Healthcare products Regulatory Agency (MHRA) operates at the intersection of science, regulation and patient impact. We enable the health system across all four UK nations to translate innovation into better outcomes.

Our role is to protect and improve public health by ensuring that people across the UK can rely on and trust in the safety, quality and effectiveness of the medicines and healthcare products they use. The MHRA has long been recognised internationally for its scientific excellence, pragmatism and leadership of global regulatory policy.

We are in the midst of extraordinary change. Scientific and technological advances are reshaping how disease is prevented, diagnosed and treated. Artificial intelligence (AI) is transforming both regulated products and how organisations are run. Cell and gene therapies are offering the possibility of long-lasting or curative treatments. Precision and personalised medicines are changing how benefit and risk must be assessed. Advanced diagnostics are driving earlier intervention and better outcomes for patients.

These ground-breaking developments challenge traditional regulatory models and require innovative approaches to evidence generation, clinical research design, manufacturing oversight, and post-market safety and surveillance.

At the same time, we are in a rapidly evolving global landscape, with regulators worldwide playing a greater role in global supply chains and market access. The choices we make now will define the MHRA's future role and promote the UK's position as a life sciences powerhouse.

Our strategy sets out how we will meet this moment and plan for the future.

Our mission is bold: Health and prosperity for all, through scientific excellence.